Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹8 Cr
Revenue (TTM)
₹1 Cr
Net Profit (TTM)
₹0 Cr
ROE
11.8 %
ROCE
2.9 %
P/E Ratio
58.7
P/B Ratio
8.9
Industry P/E
44.74
EV/EBITDA
68.3
Div. Yield
0 %
Debt to Equity
2.8
Book Value
₹0.9
EPS
₹0.1
Face value
2
Shares outstanding
10,250,800
CFO
₹-1.46 Cr
EBITDA
₹-3.98 Cr
Net Profit
₹-6.00 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Hindustan Bio Sciences
| 55.4 | 7.6 | 48.6 | 17.3 | -- | 22.1 | 11.9 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Hindustan Bio Sciences
| -45.9 | 11.6 | 135.4 | -29.9 | 15.2 | 122.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Hindustan Bio Sciences
|
8.2 | 8.4 | 1.1 | 0.1 | 8.6 | 16.2 | 58.7 | 8.9 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Hindustan Bio Sciences Limited operates in pharmaceutical and biotechnology sectors in India. It offers recombinant human erythropoietin, a glycoprotein hormone that controls erythropoiesis or red blood cell production. The company also manufactures... and markets a range of finished dosage forms of pharmaceutical products, including dry and liquid injectables, liquid/dry syrups, eye/ear/nasal drops, and pre-filled syringes, as well as non-sterile/sterile ointments, tablets, and capsules. In addition, it engages in the trading of drugs and medicines. The company also exports its products. Hindustan Bio Sciences Limited was incorporated in 1991 and is based in Hyderabad, India. Read more
Incorporated
1991
Chairman
J V R Mohan Raju
Managing Director
J V R Mohan Raju
Headquarters
Hyderabad, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of Hindustan Bio Sciences Ltd is ₹8.19 (BSE) as of 02-Apr-2026 IST. Hindustan Bio Sciences Ltd has given a return of 17.34% in the last 1 years.
The P/E ratio of Hindustan Bio Sciences Ltd is 58.71 times as on 02-Apr-2026, a 31 premium to its peers’ median range of 44.74 times.
The P/B ratio of Hindustan Bio Sciences Ltd is 8.93 times as on 02-Apr-2026, a 188 premium to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
71.05
|
7.91
|
|
2024
|
129.03
|
9.24
|
|
2023
|
0.00
|
7.30
|
|
2022
|
0.00
|
5.50
|
|
2021
|
0.00
|
2.36
|
The 52-week high and low of Hindustan Bio Sciences Ltd are Rs 10.32 and Rs 5.00 as of 05-Apr-2026.
Hindustan Bio Sciences Ltd has a market capitalisation of ₹ 8 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Hindustan Bio Sciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.39
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.